一名在干细胞移植前接受静脉注射白消安的儿童出现了意外高的AUC水平。 - Suppr | 超能文献

Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation.

作者信息

Nishikawa T, Okamoto Y, Tanabe T, Shinkoda Y, Kodama Y, Higashi M, Hirano H, Arita K, Kawano Y

出版信息

Bone Marrow Transplant. 2010 Mar;45(3):602-4. doi: 10.1038/bmt.2009.195. Epub 2009 Aug 17.

DOI:10.1038/bmt.2009.195

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Unexpectedly high AUC levels in a child who received intravenous busulfan before stem cell transplantation.一名在干细胞移植前接受静脉注射白消安的儿童出现了意外高的AUC水平。

Bone Marrow Transplant. 2010 Mar;45(3):602-4. doi: 10.1038/bmt.2009.195. Epub 2009 Aug 17.

2

Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.静脉注射白消安试验剂量的药代动力学指导剂量调整，以在接受造血干细胞移植的低强度预处理方案的儿童中实现每日单次静脉注射白消安的最佳曲线下面积。

Biol Blood Marrow Transplant. 2006 Apr;12(4):472-9. doi: 10.1016/j.bbmt.2005.12.028.

3

Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.与传统口服白消安相比，每日一次静脉注射白消安并进行治疗药物监测可提高接受异基因干细胞移植儿童的生存率和植入率。

Biol Blood Marrow Transplant. 2008 Jan;14(1):88-98. doi: 10.1016/j.bbmt.2007.09.015.

4

Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant.接受低强度预处理干细胞移植的儿童每日静脉注射一次白消安的年龄依赖性药代动力学特征。

Bone Marrow Transplant. 2009 Aug;44(3):145-56. doi: 10.1038/bmt.2008.437. Epub 2009 Feb 2.

5

Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.在接受骨髓清除性匹配同胞供体 BMT 治疗镰状细胞病的儿童中，靶向白消安治疗的安全性和有效性。

Bone Marrow Transplant. 2011 Jan;46(1):27-33. doi: 10.1038/bmt.2010.60. Epub 2010 Mar 22.

6

Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.儿童异基因造血干细胞移植中静脉用白消安的安全性、疗效和药代动力学。

Pediatr Blood Cancer. 2010 Feb;54(2):291-8. doi: 10.1002/pbc.22227.

7

High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.高剂量三氧化二砷预处理造血干细胞移植。

Expert Opin Investig Drugs. 2010 Oct;19(10):1275-95. doi: 10.1517/13543784.2010.517744.

8

A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia.一项关于靶向、剂量递增静脉注射白消安联合依托泊苷作为急性髓性白血病自体干细胞移植清髓疗法的I期研究。

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):377-83. doi: 10.1016/j.clml.2015.02.016. Epub 2015 Feb 14.

9

Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.多发性骨髓瘤患者接受白消安和美法仑大剂量减瘤治疗进行自体造血干细胞移植后发生的肝静脉闭塞病

Biol Blood Marrow Transplant. 2007 Dec;13(12):1448-54. doi: 10.1016/j.bbmt.2007.08.002.

10

Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.开发并验证了一种每日一次静脉注射白消安的测试剂量策略：固定输注率给药的重要性。

Biol Blood Marrow Transplant. 2012 Feb;18(2):295-301. doi: 10.1016/j.bbmt.2011.07.015. Epub 2011 Jul 27.

引用本文的文献

1

Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients.静脉注射白消安的谷浓度监测，以估算儿科造血干细胞移植受者血浆药物浓度-时间曲线下面积。

Int J Hematol. 2015 Nov;102(5):611-6. doi: 10.1007/s12185-015-1853-6. Epub 2015 Aug 5.

2

Pharmacokinetic monitoring is still required for intravenous busulfan in SCT for small children.对于小儿造血干细胞移植中静脉注射白消安的情况，仍需要进行药代动力学监测。

Int J Hematol. 2010 May;91(4):728-30. doi: 10.1007/s12185-010-0572-2. Epub 2010 Apr 27.